News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
AOL.com Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
SOPHiA GENETICS CTO Abhimanyu Verma sold 5,000 shares of the company's stock for $38,000, reducing his total holdings to 182,171 shares. This sale, executed under a Rule 10b5-1 trading plan, follows several other recent insider transactions. Despite the stock trading near its 12-month high, …
Sei Investments Co. has acquired 357,888 shares of SOPHiA GENETICS SA (NASDAQ:SOPH) for approximately $1.77 million, giving it a 0.52% stake in the company. Despite this institutional investment, SOPHiA GENETICS remains unprofitable, reporting a quarterly loss of $0.26 per share, worse than estimates, although …
SOPHiA GENETICS (SOPH) has filed a Form 144 indicating a proposed sale of 20,000 common shares with an aggregate market value of $133,800.00, anticipated on August 7, 2026. This filing also details previous Rule 10b5-1 plan sales by Jurgi Camblong, including significant transactions on …
HC Wainwright has lowered its FY2029 earnings per share forecast for SOPHiA GENETICS (NASDAQ: SOPH) to $0.31 from $0.34, while maintaining a Buy rating and a $14 price target. The company recently reported a quarterly loss of $0.26 per share, missing consensus estimates, despite …
SOPHiA GENETICS (NASDAQ:SOPH) insider Zhenyu Xu sold 10,000 shares of the company's stock on August 4th, reducing their position by 1.64%. The transaction, valued at $69,200, was conducted under a pre-arranged Rule 10b5-1 plan. Despite the insider sale and a recent stock dip, analysts …
SOPHiA GENETICS has announced a multi-year global partnership with AstraZeneca to develop and launch two companion diagnostics for precision oncology therapies. This collaboration aims to create decentralised clinical trial assays and diagnostic solutions for both solid tumors and blood cancers. The goal is to …
SOPHiA GENETICS Chairman Jurgi Camblong sold 20,000 shares of the company's stock for $138,400 under a pre-arranged Rule 10b5-1 plan, reducing his ownership by 0.57%. This insider sale comes amidst mixed quarterly results where revenue exceeded expectations but the company reported a larger-than-anticipated loss …
SOPHiA GENETICS SA (NASDAQ:SOPH) published its Q2 2026 earnings call presentation, reporting an EPS of -$0.20, which beat estimates by $0.02. The company also announced revenue of $23.31M, representing a 27.22% year-over-year increase and beating expectations by $1.60M. The slide deck was released in …
SOPHiA GENETICS (SOPH) has filed its Q2 2026 Form 6-K with the SEC, which includes unaudited interim financial statements and management discussion. This filing provides transparency to investors regarding the company's financial performance and operational trends. While analysts rate SOPH as a Buy with …
SOPHiA GENETICS (NASDAQ:SOPH) reached a new 52-week high following an analyst upgrade from BTIG Research, which raised its price target from $8 to $9 and maintained a Buy rating. The company reported strong Q2 2026 revenue of $23.3 million, a 27% year-over-year increase, and …
SOPHiA GENETICS SA has pre-announced positive earnings, with estimated FY26 revenue now ranging from $94-$96 Million, an increase from the previous estimate of $92-$94 Million. This positive revision is part of a broader trend of news surrounding the company's collaborations and financial performance. The …
BTIG Research has raised its price target for SOPHiA GENETICS (NASDAQ:SOPH) to $9.00 from $8.00, maintaining a "buy" rating and suggesting a 31.58% upside. This positive outlook follows the company's Q2 2026 revenue beat, an increased full-year revenue outlook of $94 million-$96 million, and …
BTIG has increased its price target for Sophia Genetics SA (NASDAQ:SOPH) to $9.00 from $8.00, maintaining a Buy rating, following the company's better-than-expected second-quarter results and two new companion diagnostics deals with AstraZeneca. Sophia Genetics reported 27% revenue growth, driven by volume increases and …
SOPHiA GENETICS announced a global, multi-year collaboration with AstraZeneca to develop and commercialize two companion diagnostics (CDx) for precision oncology therapies. This partnership aims to integrate SOPHiA GENETICS's decentralized clinical trial assays and CDx capabilities to support AstraZeneca's treatments, focusing on both solid tumor …
Jurgi Camblong, an insider at SOPHiA GENETICS SA (SOPH), has filed a notice to sell 20,000 common shares totaling $113,800.00, with the sale expected on August 4, 2026. This filing also discloses previous Rule 10b5-1 sales, including 20,000 shares sold on July 21, 2026, …
SOPHiA GENETICS insider Zhenyu Xu plans to sell 10,000 shares of common stock on NASDAQ, valued at approximately $56,900. These "Founders Shares" were acquired in 2012, and the sale is being conducted through Morgan Stanley Smith Barney LLC Executive Financial Services under a Rule …
Sophia Genetics (SOPH) reported record Q2 2026 revenue of $23.3 million, a 27% year-over-year increase, driven by strong U.S. and liquid biopsy revenue growth. The company raised its full-year 2026 revenue guidance to $94-$96 million and improved its adjusted EBITDA loss. Key strategic wins …
SOPHiA GENETICS SA filed a Form 6-K Current Report (Foreign Issuer) with the SEC on August 4, 2026, which includes unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2026, and management's discussion and analysis of financial condition …
H.C. Wainwright has reiterated a Buy rating and a $12.00 price target for Sophia Genetics (NASDAQ:SOPH) ahead of its Q2 earnings report. The firm projects Q2 revenue of $22.1 million and analysis volume of 110,000, following strong Q1 results and reaffirmed full-year 2026 revenue …
Sophia Genetics SA (SOPH) currently holds a financial score of 6.49, placing it 348th out of 485 in the Software & IT Services industry. The company's financial status is stable, though its operating efficiency is low. In its latest quarter, Sophia Genetics SA reported …
Philippe Menu, an insider at SOPHiA GENETICS (NASDAQ:SOPH), sold 5,000 shares of the company's stock for $28,300 at an average price of $5.66. This transaction was part of a pre-arranged Rule 10b5-1 trading plan and reduced his position by 2.19%. The company's stock is …
SOPHiA GENETICS (NASDAQ:SOPH) Chairman Jurgi Camblong sold 24,381 shares of the company's stock for $153,356.49, reducing his ownership by 0.69%. This sale, part of a Rule 10b5-1 plan, is one of several recent transactions totaling over 150,000 shares sold since June. The stock currently …
SOPHiA GENETICS (SOPH) is scheduled to release its Q2 2026 earnings before market open on Tuesday, August 4th. Analysts forecast a loss of $0.21 per share and revenue of $21.72 million for the quarter. The company's stock recently opened at $5.65, and insider sales …
This article details the shareholder structure of Sophia Genetics SA (SOPH), listing its major shareholders and their proportional holdings, as well as a breakdown of shareholder types. It also provides institutional shareholding data over recent quarters, showing the number of institutions, shares held, and …
This article provides the quarterly and annual cash flow statements for Sophia Genetics SA (SOPH), including operating, investing, and financing cash flows, along with related frequently asked questions. It details key financial figures such as net income, capital expenditures, and free cash flow over …
SOPHiA GENETICS SA (NASDAQ:SOPH) has received a consensus "Hold" rating from analysts, with an average 12-month price target of $9.00. While the company's latest quarterly revenue exceeded estimates, it reported a wider-than-expected loss and is still projected to remain unprofitable this year. Insiders have …
Zacks Research upgraded SOPHiA GENETICS (NASDAQ:SOPH) to a "Hold" rating, though the stock has been trading down 1.5% near its 52-week high. Despite some positive sentiment from other analysts regarding its long-term growth and potential profitability by FY2028, the company continues to post weak …
HC Wainwright has reiterated a "Buy" rating and a $12.00 price target for SOPHiA GENETICS (NASDAQ:SOPH), estimating a Q2 2026 loss of $0.15 per share. The firm projects profitability for SOPHiA GENETICS by FY2028. Despite missing Q2 2026 EPS expectations at $(0.27), the company …
SOPHiA GENETICS (SOPH) has announced that an affiliate, through Morgan Stanley Smith Barney LLC Executive Financial Services, has filed to sell up to 37,000 founders shares on NASDAQ, valued at $234,210.00. The SEC filing also details previous sales by Jurgi Camblong under a Rule …
Search by ticker symbol or company name and select a result to open its chart.